CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) is a family of DNA sequences in bacteria that contains fragment of DNA from viruses.
Several research works is going on genetically modified viruses that are efficient for bacteria to kill themselves could be the next step in fighting antibiotic-resistant infections.

Many companies have engineered such viruses, named as bacteriophages, to use the CRISPR gene-editing system to kill specific bacteria, according to a presentation at the CRISPR 2017 conference in Big Sky, Montana. These companies could begin clinical trials of therapies as soon as next year.
A French start-up company has urged the development of more powerful drugs to combat antibiotic-resistant diseases. With that in mind, the company called Eligo Bioscience has introduced a new kind of drug, Eligobiotics that are able to attack bacteria in a more focused way.
Taking Advantage of CRISPR
Possibly the most attractive thing about Eligobiotics is how it uses CRISPR the new method of gene editing to scan the bacteria and delivery precise cuts to its genetic code to wipe it out completely. In the past, CRISPR has been used to create crops, edit embryos to better understand human development, and could one day cure sickle-cell disease.
If everything goes well between trial in mice and eventual human trials Eligobiotics could be taken as a pill instead of an injection.
“This is a bit futuristic, but eventually we envision having a pill that will clean your microbiome daily,” Duportet said to Business Insider. “It’s the ultimate form of personalized medicine.”